Skip to main content Skip to navigation
CD5 APC
Product Details
Down Arrow Up Arrow


BD™
LEU1; Leu-1; Lymphocyte antigen T1; T1; LY1; Tp67
Human
Mouse BALB/c IgG2a, κ
Human T-cell acute lymphoblastic leukemia (T-ALL) cells
Flow cytometry
6.25 μg/mL
5 μL
II T7
921
Phosphate buffered saline with gelatin and 0.1% sodium azide.
ASR


Preparation And Storage

Store vials at 2°C to 8°C. Conjugated forms should not be frozen and should be protected from exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

340658 Rev. 1
Antibody Details
Down Arrow Up Arrow
L17F12

The CD5 antibody, clone L17F12, is derived from the hybridization of NS-1/Ag4 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human T-acute lymphoblastic leukemia (ALL) cells.

The CD5 antibody is composed of mouse IgG2a heavy chains and kappa light chains.

340658 Rev. 1
Format Details
Down Arrow Up Arrow
APC
Allophycocyanin (APC), is part of the BD family of phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 651 nm and an emission maximum (Em Max) at 660 nm. APC is designed to be excited by the Red (627-640 nm) laser and detected using an optical filter centered near 660 nm (e.g., a 660/20 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
APC
Red 627-640 nm
651 nm
660 nm
340658 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "340658" on CiteAb

Development References (9)

  1. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody.. Proc Natl Acad Sci USA. 1981; 78(3):1791-5. (Biology). View Reference
  2. Gadol N, Ault KA. Phenotypic and functional characterization of human Leu-1 (CD5) B cells. J Histochem Cytochem. 1986; 93:23. (Biology).
  3. Knowles RW. Immunochemical analysis of the T-cell–specific antigens. In: Reinherz EL. Ellis L. Reinherz .. et al., ed. Leukocyte typing II. New York: Springer-Verlag; 1986:259-288.
  4. Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med. 1981; 153(2):310-323. (Biology). View Reference
  5. Ledbetter JA, Frankel AE, Herzenberg. Human Leu T-cell differentiation antigens: quantitative expression on normal lymphoid cells and cell lines. In: Hammerling G, Hammerling U, Kearney J, ed. Monoclonal Antibodies and T Cell Hybridomas: Perspectives and Technical News. New York: Elsevier/North Holland Biomedical Press; 1981:16-22.
  6. Royston I, Majda JA, Baird SM, Meserve BL, Griffiths JC. Human T-cell antigens defined by monoclonal antibodies: The 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol. 1980; 125:725. (Biology).
  7. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma.. N Engl J Med. 1980; 303(6):293-300. (Biology). View Reference
  8. Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotinavidin-horseradish peroxidase method. J Histochem Cytochem. 1980; 28:771-776. (Biology).
  9. Zipf TF, Fox RI, Dilley J, Levy R. Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies.. Cancer Res. 1981; 41(11 Pt 2):4786-9. (Biology). View Reference
View All (9) View Less
340658 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.